https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / J Cancer 2011;2:357-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / J Cancer 2011;2:357-92011-06-15 00:00:002019-02-15 08:52:49Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-15 / Expert Opin Biol Ther 2011 Aug;11(8):997-10092011-06-15 00:00:002019-02-15 08:52:50Recent advances in immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)2011-06-06 11:53:442019-07-17 11:54:11Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 9541)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 9541)2011-06-05 00:00:002011-06-05 00:00:00Pilot immunotherapy trial in high-risk pediatric sarcomas.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)2011-06-05 00:00:002011-06-05 00:00:00Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)2011-06-04 11:42:372019-07-17 11:43:10Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 2533)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 2533)2011-06-04 00:00:002011-06-04 00:00:00A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)2011-06-04 00:00:002011-06-04 00:00:00Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-4032011-06-03 00:00:002019-02-15 08:40:03Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / J. Immunother. 2011 Jun;34(5):409-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / J. Immunother. 2011 Jun;34(5):409-182011-06-01 00:00:002019-02-15 08:36:02PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
